新华制药 (000756.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

13.0x

EV/EBITDA

10.0x

Market Cap

CNY 9.18B

MomentumView details →

1D Return

−2.95%

YTD Return

−14.47%

RSI (14)

42.4

ValuationView details →

P/E (Fwd)

13.0x

EV/EBITDA

10.0x

Market Cap

CNY 9.18B

RSI (14)

42.4

MomentumView details →

1D Return

−2.95%

YTD Return

−14.47%

ProfitabilityView details →

Gross Margin

18.63%

Net Margin

2.99%

EBITDA Margin

10.91%

ROE (TTM)

4.89%

ROA (TTM)

2.89%

Asset Turnover

0.96x

GrowthView details →

Revenue YoY

+3.88%

EPS YoY

−38.10%

FCF YoY

+144.08%

Revenue CAGR 3Y

+5.28%

EPS CAGR 3Y

−12.17%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.17

EPS Surprise

0.00%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.27

Avg Surprise (4Q)

0.00%

Rev Surprise

0.00%

Capital & dividendView details →

Debt/Equity

0.26x

Current Ratio

1.76x

Quick Ratio

1.23x

Div Yield

1.14%

Div Rate

CNY 0.15

Div Growth 1Y

−40.00%

Financials snapshotView financials →

Revenue (TTM)

8.75B

Net Income (TTM)

261.70M

Op. CF (TTM)

408.75M

Next earningsOct 23, 2026 →

Latest newsMore news →

Xinhua Pharmaceutical's wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical received approval for its azithromycin tablets 0.25g to pass generic drug consistency evaluation, enabling market entry.4d ago

Xinhua Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for its dapoxetine hydrochloride tablets, a 30mg Class 4 chemical prescription drug for treating premature ejaculation in men aged 18-64, approved in August 2026.7d ago

Similar companies

兴瑞科技002937.SZ 探路者300005.SZ 富祥股份300497.SZ ST天际002759.SZ 新开源300109.SZ 伊之密300415.SZ Find similar companies →

Latest newsMore news →

Xinhua Pharmaceutical's wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical received approval for its azithromycin tablets 0.25g to pass generic drug consistency evaluation, enabling market entry.4d ago Xinhua Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for its dapoxetine hydrochloride tablets, a 30mg Class 4 chemical prescription drug for treating premature ejaculation in men aged 18-64, approved in August 2026.7d ago